Breaking News Instant updates and real-time market news.

DOVA

Dova Pharmaceuticals

$16.00

0.5 (3.23%)

, RIGL

Rigel Pharmaceuticals

$1.71

0.015 (0.89%)

16:55
09/19/19
09/19
16:55
09/19/19
16:55

Wedbush biotech analysts to hold a dinner meeting

Biotech Analysts Nierengarten & Chico, along with Dr. Hanny Al-Samkari a specialist in Hematology/Oncology at Massachusetts General Hospital, assess the ITP therapeutic competitive landscape at a Dinner Meeting being held in Boston on September 19 hosted by Wedbush.

DOVA

Dova Pharmaceuticals

$16.00

0.5 (3.23%)

RIGL

Rigel Pharmaceuticals

$1.71

0.015 (0.89%)

ARGX

Argenx

$126.44

-0.94 (-0.74%)

MNTA

Momenta

$13.35

-0.14 (-1.04%)

AMGN

Amgen

$195.64

0.67 (0.34%)

NVS

Novartis

$86.39

0.09 (0.10%)

ALNY

Alnylam

$84.68

-0.87 (-1.02%)

  • 19

    Sep

  • 19

    Sep

  • 20

    Sep

  • 24

    Sep

  • 25

    Sep

  • 27

    Sep

  • 27

    Sep

  • 02

    Oct

  • 24

    Oct

  • 04

    Feb

DOVA Dova Pharmaceuticals
$16.00

0.5 (3.23%)

08/29/19
08/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) initiated with a Buy at Loop Capital. 2. Exponent (EXPO) initiated with a Neutral at DA Davidson. 3. Dova Pharmaceuticals (DOVA) initiated with an Outperform at Oppenheimer. 4. Cree (CREE) initiated with an Underperform at Exane BNP Paribas. 5. MarketAxess (MKTX) initiated with a Hold at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/29/19
08/29/19
INITIATION
Target $30

Outperform
Oppenheimer bullish on Dova Pharmaceuticals, initiates with an Outperform
As previously reported, Oppenheimer analyst Justin Kim started coverage of Dova Pharmaceuticals with an Outperform rating and $30 price target. In the midst of a commercial expansion into chronic immune thrombocytopenia, the analyst views the company's Doptelet - a thrombopoietin receptor agonist, treating plateletrelated deficiencies - as a best-in-breed therapy for an already defined commercial market. In the $1B U.S. ITP market alone, Kim believes strong commercial execution could re-rate the shares.
08/28/19
OPCO
08/28/19
INITIATION
Target $30
OPCO
Outperform
Dova Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer started Dova Pharmaceuticals with an Outperform rating and $30 price target.
09/19/19
HCWC
09/19/19
NO CHANGE
Target $45
HCWC
Buy
Dova Pharmaceuticals price target raised to $45 from $39 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Dova Pharmaceuticals to $45 from $39 saying the top-line data readout of the Phase 3 Doptelet trial in chemotherapy-induced thrombocytopenia is approaching shortly, expected in the first half of 2020. The analyst sees see upside potential for Dova in chemotherapy-induced thrombocytopenia as there are no approved therapies for it. He keeps a Buy rating on Dova Pharmaceuticals.
RIGL Rigel Pharmaceuticals
$1.71

0.015 (0.89%)

01/07/19
PIPR
01/07/19
NO CHANGE
Target $8
PIPR
Overweight
Rigel update points to 'another beat' for Tavalisse revenue, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond calculates from the update disclosed by Rigel Pharmaceuticals that the company shipped 903 bottles of Tavalisse in Q4, which he noted represents about a 39% quarter-over-quarter increase. Assuming consistent gross to net in Q3 and Q4, this implies Q4 revenue in the range of $6.8M, according to Raymond, whose revenue estimate for Rigel had been $5.2M. He also noted that the FactSet consensus revenue estimate of $35M includes a $30M upfront payment from Kissei. Raymond keeps an Overweight rating on Rigel, stating that he remains "encouraged" by the Tavalisse ITP launch.
01/23/19
PIPR
01/23/19
NO CHANGE
PIPR
Overweight
Piper says Grifols deal brings Rigel a 'step closer' to positive cash-flow
After Rigel (RIGL) announced an agreement with Grifols (GRFS) to market Tavalisse in Europe and Turkey, Piper Jaffray analyst Christopher Raymond said he believes the $30M upfront payment and $20M on EU approval should enable Rigel to reach cash flow positivity without additional financings. Citing this, and continued traction in the U.S. for Tavalisse, Raymond keeps an Overweight rating on Rigel shares.
01/23/19
HCWC
01/23/19
NO CHANGE
Target $8
HCWC
Buy
H.C. Wainwright boosts Rigel target to $8 on European partnership
H.C. Wainwright analyst Joseph Pantginis raised his price target for Rigel Pharmaceuticals to $8 from $7.50 saying the company checked an "important box" by signing a partnership for Europe with Grifols (GRFS). The analyst is "pleased" with the Grifols partnership and the terms, "especially the royalty." He's confident Rigel is working on different fronts to boost fostamatinib's clinical and commercial potential outside the U.S. and reiterates a Buy rating on the shares.
02/28/19
PIPR
02/28/19
NO CHANGE
Target $8
PIPR
Overweight
Rigel Pharmaceuticals's Tavalisse seeing continued uptake, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $8 price target on Rigel Pharmaceuticals after Q4 results indicated "continued uptake of Tavalisse". The analyst says the company is benefiting from the "improvements in physician awareness and an expanding sales force serving as growth levers that will continue into 2019." Raymond adds that the pipeline efforts of Rigel Pharmaceuticals are on track with its Phase 3 wAIHA trial set to start in the first half of this year.
ARGX Argenx
$126.44

-0.94 (-0.74%)

08/12/19
08/12/19
NO CHANGE

Argenx management to meet with Wedbush
Dinner Meeting with President Van Hauwermeiren to be held in New York on August 12 hosted by Wedbush.
03/18/19
BTIG
03/18/19
INITIATION
BTIG
Neutral
Momenta initiated with a Neutral at BTIG
BTIG analyst Thomas Shrader initiated Momenta (MNTA) with a Neutral rating, saying that while he is positive on the company's IVIg-focused re-positioning, the stock is not cheap and the proof-of-concept for its analytical focus is at least a year away. The analyst also states that the bulk of his modeled value for the company comes from its pipeline development in treating maternal-fetal autoimmune disease, noting that competition in the space is "fierce" and that Momenta is "significantly behind Argenx (ARGX) in the development of FcRn blockers.
06/27/19
BARD
06/27/19
INITIATION
Target $170
BARD
Outperform
Argenx initiated with an Outperform at Baird
Baird analyst Michael Ulz initiated Argenx with a Buy and $170 price target telling investors it has a differentiated antibody platform and has built a robust pipeline. Ulz said efgartigimod has demonstrated a best-in-class profile with potential across multiple autoimmune diseases, and early data for cusatuzumab in AML looks promising. This combined with validating partnerships and multiple catalysts over the next two years support continued upside, the analyst wrote in a note to investors.
05/23/19
PIPR
05/23/19
NO CHANGE
Target $182
PIPR
Overweight
Argenx price target raised to $182 from $161 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Argenx to $182 from $161 after the company debuted two first-in-class antibodies, ARGX-117 and ARGX-118. ARGX-117 is a C2 inhibitor with broad applicability in complement-mediated diseases including neuromuscular and kidney indications, while ARGX-117 is engineered with NHance technology to enable a "sweeping" mechanism that prevents lysosomal degradation and extends pharmacodynamic effect, Tenthoff tells investors in a research note. The analyst believes Argenx is competitively positioned from FcRn competitors with development of both intravenous and subcutaneous efgartigimod formulations. He reiterates an Overweight rating on the shares.
MNTA Momenta
$13.35

-0.14 (-1.04%)

06/06/19
WELS
06/06/19
NO CHANGE
WELS
Wells says filings indicate resolution of Amphastar dispute with Sandoz/Momenta
Wells Fargo analyst David Maris maintained an Outperform rating and $29 price target on Amphastar (AMPH) after finding "several recently filed legal motions related to the ongoing legal dispute between Amphastar and Sandoz/Momenta." Maris believes, based on these filings, that Amphastar has reached a resolution in its patent and anti-trust legal dispute with Momenta (MNTA) and Sandoz regarding enoxaparin.
05/02/19
PIPR
05/02/19
NO CHANGE
Target $35
PIPR
Overweight
Piper Jaffray 'bullish' on Momenta following Q1 results
Piper Jaffray analyst Danielle Brill maintained an Overweight rating and $35 price target on Momenta following the company's Q1 results, saying Momenta continued to advance its pipeline in the quarter, initiating Phase 2 trials with M281, its anti-FcRn candidate, in hemolytic disease of the fetus and newborn and myasthenia gravis, as well as a Phase 1/2 proof-of-concept trial of M254, a hyper-sialyated IVIG, for idiopathic thrombocytopenic purpura, adding that all trials are reportedly progressing as planned. Brill says she remains "bullish" on Momenta, and notes significant unrealized pipeline value even though proof-of-concept data are now less than 12 months out.
03/18/19
03/18/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Western Asset Mortgage (WMC) initiated with a Market Perform at Keefe Bruyette. 2. Cars.com (CARS) initiated with a Neutral at Goldman Sachs. 3. Super League Gaming (SLGG) initiated with an Outperform at Northland. 4. Arcus Biosciences (RCUS) initiated with a Buy at BTIG, while Momenta (MNTA) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/19
PIPR
09/17/19
NO CHANGE
Target $35
PIPR
Overweight
Momenta risk/reward 'extremely favorable' into M254 data, says Piper Jaffray
Proof-of-concept data from Momenta Pharmaceuticals' two key programs are expected next year. While most investors are well versed on anti-FcRn antibody M281, data from the lesser known hypersialylated IVIg program M254 will actually readout first in the first half of 2020, Piper Jaffray anlayst Danielle Brill tells investors in a research note. The analyst, who admits it is "nearly impossible" to have conviction that M254 will be successful in its ongoing clinical proof-of-concept trial since all data thus far were generated in mouse models, thinks Momenta's "extremely favorable risk/reward" makes the stock worth buying. She believes Momenta's current valuation is entirely supported by M281 and that the stock could rally 150% if M254's Phase 1/2 trial is successful. Brill keeps an Overweight rating on the shares with a $35 price target.
AMGN Amgen
$195.64

0.67 (0.34%)

09/19/19
09/19/19
NO CHANGE

Amgen management to meet with Oppenheimer
Meetings to be held in Europe on September 19-20 hosted by Oppenheimer.
09/12/19
LEER
09/12/19
NO CHANGE
LEER
Market Perform
Amgen halt of enrollment for cardiac toxicity 'unexpected,' says SVB Leerink
SVB Leerink analyst Geoffrey Porges said Amgen's disclosure earlier this morning that Phase 1 enrollment for AMG397 and AMG176 studies has been halted due to cardiac toxicity safety signals was unexpected. While not specific to AMG176 or AMG397, there is some pre-clinical evidence that MCL-1 inhibition can induce rapid and fatal heart failure, the analyst stated. Porges said he has not yet included revenue for AMG176 in his model, but having this product in the portfolio "added to the attractiveness of Amgen's stock," stated the analyst, who keeps a Market Perform rating on Amgen shares.
09/09/19
JEFF
09/09/19
NO CHANGE
Target $235
JEFF
Buy
Jefferies sees blockbuster drug for Amgen, says buy shares on selloff
Amgen's new lung data shows a 54% overall response rate at the high dose, which is "very strong," yet at the lower end of Street expectations, Jefferies analyst Michael Yee tells investors in a research note. The analyst says his thesis remains "very positive" and that Amgen should be bought on any weakness today following the data. AMGN-510 "looks like a blockbuster drug," says Yee, who keeps a Buy rating on Amgen with a $235 price target.
09/09/19
CANT
09/09/19
NO CHANGE
Target $81
CANT
Neutral
Cantor warrants caution on Mirati after Amgen data, sees 7%-11% selloff
Cantor Fitzgerald analyst Varun Kumar warrants caution on shares of Mirati Therapeutics (MRTX) ahead of its MRTX849 data following Amgen's (AMGN) update from its KRAS G12C program, AMG 510. Updated response rates data "are not a 'slam dunk' as may have been broadly expected, and further follow-up is needed for a more-matured verdict," Kumar tells investors in a research note. Further, durability will likely be the talking point in the near term, as KRASi G12C market size needs to be carefully assessed versus what's currently reflected by market estimates, adds the analyst. He thinks Mirati shares could trade down 7%-11% given some caution on the response rate trend as the cohort size gets larger and due to an increasing focus on response durability, which he thinks may change the U.S. peak sales estimates for KRAS G12C non-small-cell lung carcinoma market to $1.8B-$3.6B. Kumar lowered his price target for Mirati Therapeutics to $81 from $85 and reiterates a Neutral rating on the name. The stock in premarket trading is down 4% to $87.27. Jefferies this morning upgraded the shares to Buy following Amgen's data.
NVS Novartis
$86.39

0.09 (0.10%)

08/13/19
OPCO
08/13/19
NO CHANGE
Target $230
OPCO
Outperform
Amgen price target raised to $230 from $210 at Oppenheimer
Oppenheimer analyst Jay Olson raised his price target for Amgen (AMGN) to $230 from $210 after the U.S. District Court determined that Sandoz has not met the burden to prove all seven asserted claims invalid and upheld several Enbrel patents. The analyst suspects Sandoz will appeal but views the outcome as highly favorable for Amgen and models flat Enbrel sales until 2021 before declining. Sandoz is a division of Novartis (NVS). Olson reiterates an Outperform rating on Amgen's shares.
08/12/19
LEHM
08/12/19
NO CHANGE
Target $31
LEHM
Overweight
Coherus should be bought on weakness from Enbrel ruling, says Barclays
Barclays analyst Balaji Prasad recommends buying shares of Coherus Biosciences (CHRS) on any weakness from Amgen's (AMGN) favorable Enbrel patent ruling against Novartis (NVS). Coherus is developing its own Enbrel generic, says the analyst, whose model already factors a launch in Q2 of 2029, following the expiration of the last U.S. Enbrel patent. As such, Prasad is making no change to his estimates following Friday's decision. He remains positive on Coherus and would use any share weakness as an opportunity to add a "fundamentally sound company." Prasad reiterates an Overweight rating on the shares with a $31 price target.
09/05/19
09/05/19
UPGRADE
Target $107

Outperform
Incyte upgraded to Outperform from Market Perform at JMP Securities
As previously reported, JMP Securities analyst Reni Benjamin assumed coverage of Incyte (INCY) with an upgraded rating of Outperform and a $107 price target. The analyst cites the "solid fundamentals" of the company's multi-billion dollar Jakafi franchise, including its recent approval in steroid refractory acute graft-versus-host disease, which he believes remains under-appreciated by investors. Benjamin is also positive on Incyte's "marquee" partners that include Novartis (NVS) and Eli Lilly (LLY), along with its $1.7B cash position, diverse pipeline, and strong fundamentals.
09/13/19
DBAB
09/13/19
NO CHANGE
DBAB
Hold
Novartis' ofatumumab to be 'strong' competitor to Roche drug, says Deutsche Bank
Deutsche Bank analyst Richard Parkes tells investors in a research note after attending the ECTRIMS conference in Stockholm that data from Novartis' (NVS) ASCLEPIOS trials suggests ofatumumab will be a "strong" competitor for Roche's (RHHBY) Ocrevus in relapsing/remitting multiple sclerosis. Parkes says he expects physicians to view the drugs as having broadly comparable and highly compelling efficacy, with ofatumumab's at-home dosing an attractive option for some patients, suggesting meaningful upside potential to his current 2024E ofatumumab sales of $1.1B and possible risks to his forecasts for Roche's Ocrevus. According to physician feedback, Parkes says the drugs are likely to share a rapidly growing market. Parkes maintains a Hold rating and 90 CHF price target on Novartis shares.
ALNY Alnylam
$84.68

-0.87 (-1.02%)

09/10/19
PIPR
09/10/19
NO CHANGE
Target $145
PIPR
Overweight
Alnylam's updated OLE data shows reduced 'daily worst pain,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $145 price target on Alnylam after the company presented new results from the Phase III ENVISION trial and Phase I/II OLE study of givosiran in Acute Hepatic Poprphyria at the International Congress on Porphyrins and Porphyrias Conference. Tenthoff says the updated OLE data showed that monthly givosiran dosing reduced median annualized attack rate to 0.22 over 30 months, and patient reported outcomes also revealed reduced "daily worst pain" for subjects receiving givosiran, lower use of opioids and improved quality of life. Tenthoff tells investors in a research note that he is "confident" in FDA approval by the February 4 PDUFA date.
09/03/19
STFL
09/03/19
NO CHANGE
Target $116
STFL
Buy
Alnylam data broadly support inclisiran as approvable drug, says Stifel
After Alnylam (ALNY) partner The Medicine Co. (MDCO) presented Phase 3 data on inclisiran at the European Society of Cardiology Congress, Stifel analyst Paul Matteis said the efficacy data were positive, but the focus is really on safety and "encouragingly" the adverse events, incidence of death, and serious adverse events all occurred at similar rates on inclisiran versus placebo. The analyst, who believes the data broadly support inclisiran as an approvable drug, also thinks the results validate Alnylam's recent efforts in non-orphan areas. Matteis, who noted that Alnylam will receive up to a 20% royalty on inclisiran sales, has a Buy rating and $116 price target on Alnylam shares.
09/02/19
PIPR
09/02/19
NO CHANGE
Target $145
PIPR
Overweight
Alnylam price target raised to $145 from $142 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam (ALNY) to $145 from $142 after partner The Medicine Co. (MDCO) presented positive Phase III ORION-11 data on inclisiran in 1,617 ASCVD patients at the European Society of Cardiology Congress in Paris. The analyst remains confident in inclisiran approval next year and Alnylam is eligible for milestones plus up to double-digit royalties. He reiterates an Overweight rating on Alnylam shares.
08/26/19
PIPR
08/26/19
NO CHANGE
PIPR
The Medicines Co. data a positive for Alnylam, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $142 price target on Alnylam Pharmaceuticals (ALNY) after its partner, The Medicines Co. (MDCO), announced positive top-line data from its Phase III ORION-11 trial of inclisiran. The analyst believes inclisiran will be approved next year, and noted that Alnylam is eligible for "milestones plus up to double-digit royalties."

TODAY'S FREE FLY STORIES

LK

Luckin Coffee

$18.99

-0.025 (-0.13%)

10:05
10/14/19
10/14
10:05
10/14/19
10:05
Options
Luckin Coffee call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVST

Envista

$27.55

-0.32 (-1.15%)

10:02
10/14/19
10/14
10:02
10/14/19
10:02
Initiation
Envista initiated  »

Envista initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EHTH

eHealth

$53.10

-2.88 (-5.14%)

10:01
10/14/19
10/14
10:01
10/14/19
10:01
Periodicals
eHealth lower following cautious Off Wall Street mention »

Shares of eHealth are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

SAFM

Sanderson Farms

$148.68

-1.2 (-0.80%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Conference/Events
Sanderson Farms to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 13

    Nov

RES

RPC, Inc.

$4.55

-0.4 (-8.08%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
RPC, Inc. falls -8.3% »

RPC, Inc. is down -8.3%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

CRC

California Resources

$8.09

-0.725 (-8.22%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
California Resources falls -9.0% »

California Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

PE

Parsley Energy

$14.79

-2.19 (-12.90%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
Parsley Energy falls -12.8% »

Parsley Energy is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 06

    Nov

UGAZ

VelocityShares 3x Long Natural Gas ETN

$13.86

0.76 (5.80%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
VelocityShares 3x Long Natural Gas ETN rises 5.9% »

VelocityShares 3x Long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NNA

Navios Acquisition

$10.18

0.64 (6.71%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
Navios Acquisition rises 6.1% »

Navios Acquisition is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$5.86

0.5 (9.33%)

10:00
10/14/19
10/14
10:00
10/14/19
10:00
Hot Stocks
Britannia Bulk rises 8.9% »

Britannia Bulk is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$14.61

0.26 (1.81%)

, PPL

PPL Corp.

$32.12

0.68 (2.16%)

09:55
10/14/19
10/14
09:55
10/14/19
09:55
Options
Early notable gainers among liquid option names on October 14th »

Notable gainers among…

HPE

HP Enterprise

$14.61

0.26 (1.81%)

PPL

PPL Corp.

$32.12

0.68 (2.16%)

WDC

Western Digital

$59.92

1.56 (2.67%)

HPQ

HP Inc.

$16.39

0.16 (0.99%)

VAR

Varian Medical

$112.20

1.42 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

  • 23

    Oct

  • 23

    Oct

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

UGAZ

VelocityShares 3x Long Natural Gas ETN

$13.90

0.8 (6.11%)

09:47
10/14/19
10/14
09:47
10/14/19
09:47
Hot Stocks
VelocityShares 3x Long Natural Gas ETN rises 6.1% »

VelocityShares 3x Long…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$5.71

0.35 (6.53%)

09:47
10/14/19
10/14
09:47
10/14/19
09:47
Hot Stocks
Britannia Bulk rises 6.8% »

Britannia Bulk is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$39.82

2.68 (7.22%)

09:47
10/14/19
10/14
09:47
10/14/19
09:47
Hot Stocks
Aecom rises 7.1% »

Aecom is up 7.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

AYTU

Aytu BioScience

$1.21

(0.00%)

09:42
10/14/19
10/14
09:42
10/14/19
09:42
Conference/Events
Aytu BioScience to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Oct

FCX

Freeport McMoRan

$9.54

(0.00%)

, WDC

Western Digital

$58.36

(0.00%)

09:40
10/14/19
10/14
09:40
10/14/19
09:40
Options
Unusually active option classes on open October 14th »

Unusual total active…

FCX

Freeport McMoRan

$9.54

(0.00%)

WDC

Western Digital

$58.36

(0.00%)

ASHR

X-trackers Harvest CSI 300

$28.16

(0.00%)

BYND

Beyond Meat

$131.40

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

FND

Floor & Decor

$48.93

0.69 (1.43%)

09:39
10/14/19
10/14
09:39
10/14/19
09:39
Recommendations
Floor & Decor analyst commentary  »

Floor & Decor price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

BOX

Box

$16.74

0.345 (2.10%)

09:36
10/14/19
10/14
09:36
10/14/19
09:36
Periodicals
Box hires Morgan Stanley as advisor amid activist push, Dealreporter says »

Faced with activist…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

REPR

RMS Medical Products

$0.00

(0.00%)

09:35
10/14/19
10/14
09:35
10/14/19
09:35
Hot Stocks
RMS Medical Products to commence trading on Nasdaq on October 17 »

Repro Med Systems, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

VRTS

Virtus Investment

$90.90

2.59 (2.93%)

09:34
10/14/19
10/14
09:34
10/14/19
09:34
Upgrade
Virtus Investment rating change  »

Virtus Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNO

Vornado

$62.65

0.46 (0.74%)

09:34
10/14/19
10/14
09:34
10/14/19
09:34
Hot Stocks
Vornado announces certain items to be included in Q3 results »

Vornado Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

CHKP

Check Point

$111.27

1.78 (1.63%)

09:32
10/14/19
10/14
09:32
10/14/19
09:32
Downgrade
Check Point rating change  »

Check Point downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 28

    Oct

  • 16

    Dec

BSMX

Santander Mexico

$6.86

0.165 (2.47%)

09:32
10/14/19
10/14
09:32
10/14/19
09:32
Upgrade
Santander Mexico rating change  »

Santander Mexico upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

09:30
10/14/19
10/14
09:30
10/14/19
09:30
General news
Oil Action: Front-month WIT are down 2.3% »

Oil Action: Front-month…

GM

General Motors

$35.57

0.9 (2.60%)

09:29
10/14/19
10/14
09:29
10/14/19
09:29
Recommendations
General Motors analyst commentary  »

Morgan Stanley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.